Korean Obesity Drug Race Intensifies as Epe Launches, With GLP-1, Muscle-Building and Patch Therapies in Development
Source · 헬스조선
TLDR
Health Chosun reports that Hanmi Pharmaceutical’s Epe has launched as Korea’s first domestically developed GLP-1 obesity treatment. Hanmi’s follow-up candidates have entered U.S. Phase 1 and Phase 2 trials, while competitors are developing multi-receptor drugs and a semaglutide microneedle patch.
- 01Hanmi’s HM15275 triple agonist is in Phase 2; HM17321, designed to reduce fat and increase muscle, is in Phase 1, with muscle-function findings reported in animals.
- 02Celltrion says its four-receptor candidate CT-G32 is undergoing toxicity testing, with a Phase 1 trial application planned by February 2027.
- 03Daewoong received approval for a Phase 1 trial plan for its semaglutide patch; Dong-A ST’s dual-agonist DA-1726 is undergoing Phase 1 testing.
Why it matters Editorial
The report highlights Korean companies’ efforts to differentiate obesity treatments through additional receptor targets, muscle-focused mechanisms and alternative delivery formats, with several candidates still in early development.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
Caribbean National Weekly
Johannesburg Sunday World
Generics and Biosimilars Initiative